Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a8cfe4d98015afb6ce0269fe898d987a http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8381805eba6d034fc77bd230dd02e6e2 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J2208-00823 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6921 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1635 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1682 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1841 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2013 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J13-0065 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-69 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B01J13-00 |
filingDate |
2017-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2019-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_947accf25ab13fdb8c19b2d1a3c49a1b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb383aa923cab6f53105fcbdb851243b |
publicationDate |
2019-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-10449151-B2 |
titleOfInvention |
Artificial cell constructs for cellular manipulation |
abstract |
The present invention contemplates induction of immunological tolerance thereby providing permanent allograft acceptance. This method obviates the need for a lifelong regimen of immunosuppressive agents which can increase the risk of infection, autoimmunity, and cancer. Immunological tolerance is thought to be mediated by regulatory T lymphocytes (Treg cells) with immunosuppressive capabilities. A therapeutically relevant platform comprising artificial constructs are contemplated comprising numerous soluble and surface bound Treg cell stimulating factors that may induce tolerance following allograft transplantation. Such artificial constructs, being the size of a cell, have surface bound monoclonal antibodies specific to regulatory T-cell surface moieties and encapsulated soluble regulatory T-cell modulating factors. |
priorityDate |
2009-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |